MabIgX® Overview

MabIgX® Antibody Discovery Platform & Development of Rare, Potent Human mAbs


The human immune system’s ability to generate highly specific, protective antibodies to foreign antigens is unmatched by any man-made technology. Antibodies that are functionally optimized by our immune system can sometimes protect even against the most lethal pathogens. As such, in virtually every infectious disease, there is a subset of the patient population that manages the infection better than the average individuals, sometimes enabling these patients subset to remain disease-free. The MabIgX technology is designed to rapidly identify rare, potent antibody-producing B-cells from patients who successfully overcame an infection. Aridis’ unique, proprietary fusion cell line immortalizes active, antibody-producing human B-cells with remarkable stability, enabling large scale manufacturing of these fully human mAbs to be used as possible therapies to protect the masses.


Unlike current antibody therapies, Aridis’ mAbs are completely of human origin, functionally optimized for high potency by the patient’s immune system, and do not require genetic engineering or further optimization to achieve full functionality and high mAb productivity. This technology also allows for the selection of any antibody isotype, depending on the optimal effector function required for treating the target infection. Bypassing the humanization, binding sequence optimization, and generation of genetically engineered antibody producing cell lines allows for a much faster progression to clinical development compared to other companies developing antibody therapies.


Key competitive advantages of Aridis’ MabIgX® technology and the resulting fully human antibodies:


  • Faster progression from target identification to clinical development (by ~1 year) as compared to conventional immunotherapy approaches involving generation of genetically engineered antibody producing cell lines
  • Antibody candidates are immunologically and medically relevant, based on specificity and isotype (e.g. IgG, IgA, IgM)
  • Superior safety profile with the potential for long term, repeated administrations
  • High affinity and selectivity may result in lower effective doses, resulting in lower cost-of-goods during large-scale production compared to traditional antibody therapies